CVS White Paper Pushes Drugmakers to Cut GLP-1 Prices to $350
CVS Health released a white paper at the HLTH conference arguing GLP-1 drugs would save employers money if priced at $350 per month or less, down from the $617-$766 employers typically pay now. Using three years of Aetna commercial claims data, CVS found GLP-1 users saw fewer hospitalizations, ER visits and cardiovascular events, saving $9,400 per person in medical costs, but plan sponsors spent $13,300 more on prescriptions, a net cost of $3,900 per person. CVS CMO Amy Compton-Phillips said the paper is meant to pressure drugmakers Eli Lilly and Novo Nordisk, noting the companies charge Medicare $245 a month for the drugs in a pilot program while charging employers far more. Employer coverage of GLP-1s is declining as costs rise, with nearly 8 in 10 employers blaming GLP-1 spending for projected cost increases next year.